New Oral GLP-1 Pill Shows Dramatic Weight Loss and Blood Sugar Results
AstraZeneca's new oral medication, elecoglipron, has just delivered significant results in its latest trials, potentially changing the landscape for millions living with type two diabetes and obesity. The drug, a small molecule glucagon-like peptide-1 receptor agonist, has successfully completed its phase two trials, paving the way for extensive phase three studies, including critical cardiovascular and kidney outcome trials. This development marks a pivotal moment for AstraZeneca's ambition to create a comprehensive portfolio of treatments for cardiometabolic and kidney diseases.
The VISTA trial focused on adults with obesity or overweight, showing that those taking elecoglipron achieved a remarkable average weight loss of ten point five percent at twenty-six weeks, compared to a mere zero point six percent with a placebo. This impressive weight reduction continued, reaching eleven point eight percent at thirty-six weeks for the one hundred and five participants in the seventy-five milligram dosage group. Furthermore, eighty-eight point eight percent of participants achieved at least a five percent weight loss, a key indicator of success in weight management.
Also Read:- Jetstars First Western Sydney Flight Revealed
- Hurricanes Cannot Afford What Just Happened In Vegas Game 4
In parallel, the SOLSTICE trial investigated elecoglipron's effect on adults with type two diabetes, demonstrating a significant reduction in their HbA1c levels. Participants on the seventy-five milligram dose saw their HbA1c, a measure of average blood sugar over two to three months, drop by one point nine percent from baseline at twenty-six weeks, far exceeding the zero point two percent reduction seen in the placebo group. This trial also revealed that eighty-five percent of participants reached an HbA1c of six point five percent or lower, a crucial target for long-term diabetes management.
Beyond these primary endpoints, elecoglipron also showed potential in improving other health markers. Exploratory analyses in the VISTA trial indicated clinically meaningful improvements in cardiometabolic risk factors, including lower blood pressure and reduced C-reactive protein levels, a marker of systemic inflammation. In the SOLSTICE trial, alongside the glycaemic control, participants also experienced a clinically meaningful average body weight reduction of seven point seven percent compared to one point seven percent with placebo.
The safety profile of elecoglipron was consistent with the known effects of glucagon-like peptide-1 receptor agonists, with the most common adverse events being gastrointestinal in nature, such as nausea, constipation, diarrhoea and vomiting and generally of mild to moderate severity. In the VISTA trial, nausea affected fifty-five percent of participants on the seventy-five milligram dose compared to twenty percent on placebo, while constipation was reported by forty-one percent versus six percent. These adverse events leading to discontinuation were infrequent and notably, no liver safety signals were observed across both trials.
Professor Melanie Davies, a leading diabetes expert and principal investigator for the VISTA trial, highlighted the significant opportunity remaining in obesity management, stating that the VISTA results show elecoglipron's potential to treat both obesity and its related complications. Dr. Vanita Aroda, principal investigator for the SOLSTICE trial, echoed this sentiment, emphasizing elecoglipron's potential to become an important treatment option for people with type two diabetes, with a vast majority reaching guideline-recommended glycaemic targets.
Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, expressed confidence in the progression of elecoglipron, underscoring the company's ambition to tackle major global diseases. The extensive phase three programme, which includes the EMBOLD and ELUMINATE trials, will further evaluate elecoglipron for obesity, with and without type two diabetes and in combination therapies, alongside crucial long-term cardiovascular and kidney outcome trials. These promising results presented at the American Diabetes Association's Scientific Sessions and published in The Lancet are a significant step forward.
Read More:
0 Comments